Cigna Investments Inc. New increased its position in shares of Bruker (NASDAQ:BRKR) by 127.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,227 shares of the medical research company’s stock after purchasing an additional 28,146 shares during the quarter. Cigna Investments Inc. New’s holdings in Bruker were worth $1,503,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently modified their holdings of BRKR. BlackRock Inc. increased its position in shares of Bruker by 7.1% during the fourth quarter. BlackRock Inc. now owns 5,173,860 shares of the medical research company’s stock worth $177,566,000 after purchasing an additional 341,389 shares in the last quarter. Sensato Investors LLC increased its position in shares of Bruker by 57.0% during the fourth quarter. Sensato Investors LLC now owns 527,658 shares of the medical research company’s stock worth $18,109,000 after purchasing an additional 191,504 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Bruker during the fourth quarter worth approximately $6,142,000. Renaissance Technologies LLC increased its position in shares of Bruker by 105.7% during the fourth quarter. Renaissance Technologies LLC now owns 262,710 shares of the medical research company’s stock worth $9,016,000 after purchasing an additional 135,000 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Bruker by 34.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 476,524 shares of the medical research company’s stock worth $16,354,000 after purchasing an additional 121,410 shares in the last quarter. Hedge funds and other institutional investors own 65.55% of the company’s stock.
A number of equities analysts have weighed in on BRKR shares. Leerink Swann boosted their price objective on Bruker from $32.00 to $34.00 and gave the stock a “market perform” rating in a research note on Friday, February 9th. Morgan Stanley lowered their price objective on Bruker from $35.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, February 9th. BidaskClub lowered Bruker from a “buy” rating to a “hold” rating in a research note on Saturday, February 10th. Bank of America lowered their price objective on Bruker from $37.00 to $34.00 and set a “neutral” rating on the stock in a research note on Friday, May 4th. Finally, BTIG Research set a $42.00 price objective on Bruker and gave the stock a “buy” rating in a research note on Sunday, May 6th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company. Bruker presently has an average rating of “Hold” and an average target price of $32.91.
Shares of Bruker stock opened at $31.17 on Tuesday. Bruker has a 52 week low of $26.00 and a 52 week high of $36.53. The firm has a market capitalization of $4.84 billion, a PE ratio of 25.76, a price-to-earnings-growth ratio of 2.04 and a beta of 1.14. The company has a current ratio of 2.22, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26.
Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, May 3rd. The medical research company reported $0.24 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.02. Bruker had a return on equity of 27.04% and a net margin of 4.63%. The business had revenue of $431.70 million for the quarter, compared to analyst estimates of $419.25 million. During the same quarter in the prior year, the company posted $0.19 EPS. The company’s quarterly revenue was up 12.2% on a year-over-year basis. equities analysts forecast that Bruker will post 1.39 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 22nd. Stockholders of record on Monday, June 4th will be paid a $0.04 dividend. This represents a $0.16 annualized dividend and a dividend yield of 0.51%. The ex-dividend date of this dividend is Friday, June 1st. Bruker’s dividend payout ratio (DPR) is presently 13.22%.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker (NASDAQ:BRKR).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.